Is VBIV A Good Stock To Buy Now?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data....
Posts Tagged ‘NASDAQ:VBIV’
Is VBI Vaccines, Inc. (VBIV) A Good Stock To Buy?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data....
Hedge Funds Have Never Been This Bullish On VBI Vaccines, Inc. (VBIV)
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse...
Hedge Fund and Insider Trading News: Sahm Adrangi, Bernard Selz, Stryker Corporation (SYK), VBI Vaccines Inc (VBIV), and More
Woodford’s Hedge Fund foe Rules out a Return to Shorting his Holdings (FNLondon.com) Kerrisdale Capital, the US hedge fund that made a public enemy...
13D Filing: Perceptive Advisors Keeps Funding Vbi Vaccines Inc
“On December 13, 2018, the Fund purchased 14,285,714 shares of Common Stock at a price of $1.40 per share,” The details of the filing can...
Hedge Fund and Insider Trading News: Eddie Lampert, Steven Cohen, Synergy CHC Corp (SNYR), Marijuana Company Of America Inc (MCOA), Cracker Barrel Old Country Store, Inc. (CBRL), and More
Kmart Was Once Rescued from Bankruptcy by Eddie Lampert. It’s Unclear Whether it will Happen Again (CNBC) Much has changed in retail over the past 16...
13D Filing: Perceptive Advisors and VBI Vaccines, Inc. (VBIV)
VBI Vaccines, Inc. (NASDAQ:VBIV): Joseph Edelman’s Perceptive Advisors filed an amended 13D. You can check out Perceptive Advisors’ latest...
13D Filing: Opko Health, Inc. and Vbi Vaccines Inc. (NASDAQ:VBIV)
You can access the original SEC filing by clicking here. Ownership Summary Table Page 1 of 5 – SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington...
VBI Vaccines, Inc. (VBIV) Gets European Support For Pivotal Phase III Sci-B-Vac Trial
Risks in biotech investment tend to increase as a young company gets closer and closer to its first FDA approval. Trials become more expensive, expectations...
$23.6M Investment From 2015’s Top Performing Hedge Fund Makes VBI Vaccines, Inc. (VBIV) Even More Undervalued
One would think that a hepatitis B vaccine with 100% efficacy, negligible safety issues, and mountains of clinical data already supporting it would be...
New Phase IV Data On VBI Vaccines, Inc. (VBIV) HBV Vaccine Show It Can Carve Out A Market From GlaxoSmithKline PLC (ADR) (GSK)
No stock is ever a sure thing, but that doesn’t mean you can’t get asymptotically close to one. Following the announcement by VBI Vaccines, Inc. (...
